Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost. 2010 Sep; 104(3):642-9.
View in:
PubMed
subject areas
Administration, Oral
Administration, Oral
Aged
Aged
Anticoagulants
Anticoagulants
Arthroplasty, Replacement, Hip
Arthroplasty, Replacement, Hip
Canada
Canada
Dalteparin
Dalteparin
Double-Blind Method
Double-Blind Method
Drug Administration Schedule
Drug Administration Schedule
Elective Surgical Procedures
Elective Surgical Procedures
Europe
Europe
Factor Xa
Factor Xa
Factor Xa Inhibitors
Factor Xa Inhibitors
Female
Female
Fibrinolytic Agents
Fibrinolytic Agents
Hemorrhage
Hemorrhage
Humans
Humans
Injections, Subcutaneous
Injections, Subcutaneous
Logistic Models
Logistic Models
Male
Male
Middle Aged
Middle Aged
Phlebography
Phlebography
Pulmonary Embolism
Pulmonary Embolism
Pyridines
Pyridines
Risk Assessment
Risk Assessment
Risk Factors
Risk Factors
Thiazoles
Thiazoles
Time Factors
Time Factors
Treatment Outcome
Treatment Outcome
United States
United States
Venous Thromboembolism
Venous Thromboembolism
Venous Thrombosis
Venous Thrombosis
authors with profiles
Gary E Raskob